/
BYSI
$1.79+$0.10 (+5.92%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$69.5M
41M shares
52-week range
$1.18 – $2.50
46% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
6.87%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-8.95
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $180.0K | $1.4M | $1.4M | $0 | $0 | $0 |
| Cost of revenue | $48.0K | $77.0K | $0 | $0 | $0 | $302.0K | $0 | $87.0K |
| Gross profit | −$48.0K | −$77.0K | $180.0K | $1.4M | $1.4M | −$302.0K | $0 | −$87.0K |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | — | — | — |
| R&D | $51.6M | $31.3M | $41.8M | $36.9M | $25.6M | $7.3M | $2.6M | $4.4M |
| Operating income | −$57.5M | −$40.3M | −$64.2M | −$66.2M | −$37.2M | −$15.1M | −$8.8M | −$8.9M |
| EBITDA | −$57.5M | −$40.0M | −$63.7M | −$64.5M | −$35.0M | −$13.6M | −$8.5M | −$8.5M |
| Net income | −$54.9M | −$38.1M | −$61.0M | −$64.2M | −$33.3M | −$21.0M | −$11.1M | −$8.0M |
| Net margin | — | — | -33873.9% | -4750.5% | -2463.3% | — | — | — |
| EPS (diluted) | -2.42 | -1.55 | -2.04 | -1.64 | -0.85 | -0.54 | -0.28 | -0.20 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $195M | $1.98 | $1.98–$1.98 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.18
Price
$1.79
Implied downside
-90%
Peer comparison
BeyondSpring Inc. Ordinary Shares
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
www.beyondspringpharma.com- Employees
- 44
- IPO / List date
- Mar 9, 2017
- HQ
- FLORHAM PARK, NJ
Held by traders on TradeandTell
No one on the platform currently holds BYSI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BYSI as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BYSI yet.
